Replies to post #130212 on Biotech Values

[genisi]

Apropos to XP21279 the prodrug of L-dopa in Parkinson's, this is a recent PR related to GSK/IPXL competitive product - IPX066, regarding its second phase III trial, which I haven't seen mentioned here :

http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-580727.htm